Literature DB >> 23482465

Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis.

Yihe Chen1, Sunil K Chauhan, Hyun Soo Lee, William Stevenson, Chris S Schaumburg, Zahra Sadrai, Daniel R Saban, Shilpa Kodati, Michael E Stern, Reza Dana.   

Abstract

PURPOSE: A majority of experimental data on dry eye disease (DED) immunopathogenesis have been derived from a murine model of DED that combines desiccating environmental stress with systemic muscarinic acetylcholine receptor (mAChR) inhibition. However, to our knowledge the effects of pharmacologic mAChR blockade on the pathogenesis of experimental DED have not been evaluated systemically. The purpose of our study was to investigate the differential effects of desiccating environmental stress and mAChR inhibition on the pathogenesis of DED.
METHODS: DED was induced in female C57BL/6 mice by exposure to a desiccating environment in the controlled-environment chamber or to systemic scopolamine, or by performing extraorbital lacrimal gland excision. Clinical disease was assessed using corneal fluorescein staining (CFS) and the cotton thread test (CTT). Corneal CD11b(+) and conjunctival CD3(+) T-cell infiltration were evaluated by flow cytometry. T-cells from draining cervical lymph nodes (CLN) and distant inguinal lymph nodes (ILN) were analyzed for Th1, Th2, Th17, and Treg responses by flow cytometry and ELISA.
RESULTS: Desiccating environmental stress and systemic mAChR blockade induced similar clinical signs of DED. However, desiccating environmental stress imparted higher conjunctival CD3(+) T-cell infiltration, and greater Th17-cell activity and Treg dysfunction than mAChR blockade, while mAChR blockade decreased tear secretion to a greater extent than desiccating environmental stress. Systemic mAChR blockade attenuated Th17 activity and enhanced Th2 and Treg responses without affecting Th1 activity.
CONCLUSIONS: In vivo inhibition of mAChRs variably affects CD4(+) T-cell subsets, and desiccating environmental stress and systemic mAChR blockade induce DED through different primary pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482465      PMCID: PMC3623599          DOI: 10.1167/iovs.12-11121

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  31 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  Role of muscarinic receptors in the regulation of immune and inflammatory responses.

Authors:  Seddigheh Razani-Boroujerdi; Muskaan Behl; Fletcher F Hahn; Juan Carlos Pena-Philippides; Julie Hutt; Mohan L Sopori
Journal:  J Neuroimmunol       Date:  2008-01-10       Impact factor: 3.478

Review 3.  Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy.

Authors:  Takeshi Fujii; Yuki Takada-Takatori; Koichiro Kawashima
Journal:  J Pharmacol Sci       Date:  2008-02-16       Impact factor: 3.337

Review 4.  Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases.

Authors:  Darlene A Dartt
Journal:  Prog Retin Eye Res       Date:  2009-04-17       Impact factor: 21.198

5.  Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies.

Authors:  Debra A Schaumberg; Reza Dana; Julie E Buring; David A Sullivan
Journal:  Arch Ophthalmol       Date:  2009-06

6.  Diminished antigen-specific IgG1 and interleukin-6 production and acetylcholinesterase expression in combined M1 and M5 muscarinic acetylcholine receptor knockout mice.

Authors:  Yoshihito X Fujii; Ayako Tashiro; Kumiko Arimoto; Hirofumi Fujigaya; Yasuhiro Moriwaki; Hidemi Misawa; Takeshi Fujii; Minoru Matsui; Tadashi Kasahara; Koichiro Kawashima
Journal:  J Neuroimmunol       Date:  2007-06-21       Impact factor: 3.478

7.  Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression.

Authors:  Sunil K Chauhan; Jaafar El Annan; Tatiana Ecoiffier; Sunali Goyal; Qiang Zhang; Daniel R Saban; Reza Dana
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

8.  IL-17 disrupts corneal barrier following desiccating stress.

Authors:  C S De Paiva; S Chotikavanich; S B Pangelinan; J D Pitcher; B Fang; X Zheng; P Ma; W J Farley; K F Siemasko; J Y Niederkorn; M E Stern; D-Q Li; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2009-02-25       Impact factor: 7.313

9.  Topical omega-3 and omega-6 fatty acids for treatment of dry eye.

Authors:  Saadia Rashid; Yiping Jin; Tatiana Ecoiffier; Stefano Barabino; Debra A Schaumberg; M Reza Dana
Journal:  Arch Ophthalmol       Date:  2008-02

10.  Transplantation of newborn lacrimal gland cells in a rat model of reduced tear secretion.

Authors:  Arie Nemet; Michael Belkin; Mordechai Rosner
Journal:  Isr Med Assoc J       Date:  2007-02       Impact factor: 0.892

View more
  23 in total

1.  IFN-γ-Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity.

Authors:  Yihe Chen; Sunil K Chauhan; Chunyi Shao; Masahiro Omoto; Takenori Inomata; Reza Dana
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

2.  Comparison of postoperative corneal changes between dry eye and non-dry eye in a murine cataract surgery model.

Authors:  Jin Woo Kwon; Yeon Woong Chung; Jin A Choi; Tae Yoon La; Dong Hyun Jee; Yang Kyung Cho
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

3.  Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease.

Authors:  Rohan Bir Singh; Tomas Blanco; Sharad K Mittal; Yukako Taketani; Sunil K Chauhan; Yihe Chen; Reza Dana
Journal:  Ocul Surf       Date:  2020-05-06       Impact factor: 5.033

4.  Desiccating stress-induced disruption of ocular surface immune tolerance drives dry eye disease.

Authors:  M Guzmán; I Keitelman; F Sabbione; A S Trevani; M N Giordano; J G Galletti
Journal:  Clin Exp Immunol       Date:  2016-02-15       Impact factor: 4.330

5.  The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease.

Authors:  Xuhua Tan; Yihe Chen; William Foulsham; Afsaneh Amouzegar; Takenori Inomata; Yizhi Liu; Sunil K Chauhan; Reza Dana
Journal:  Ocul Surf       Date:  2018-07-25       Impact factor: 5.033

6.  CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease.

Authors:  Shilpa Kodati; Sunil K Chauhan; Yihe Chen; Thomas H Dohlman; Parisa Karimian; Daniel Saban; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-19       Impact factor: 4.799

Review 7.  Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.

Authors:  Marjan Farid; Anshu Agrawal; Daniel Fremgen; Jeremiah Tao; He Chuyi; Anthony B Nesburn; Lbachir BenMohamed
Journal:  Ocul Immunol Inflamm       Date:  2014-12-23       Impact factor: 3.070

8.  Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.

Authors:  Jin Woo Kwon; Jin A Choi; Eun Young Shin; Tae Yoon La; Dong Hyun Jee; Yeon Woong Chung; Yang Kyung Cho
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

Review 9.  Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Authors:  Anthony J St Leger; Rachel R Caspi
Journal:  Bioessays       Date:  2018-10-05       Impact factor: 4.345

10.  Pigment Epithelium-Derived Factor Enhances the Suppressive Phenotype of Regulatory T Cells in a Murine Model of Dry Eye Disease.

Authors:  Rohan B Singh; Tomas Blanco; Sharad K Mittal; Hamid Alemi; Sunil K Chauhan; Yihe Chen; Reza Dana
Journal:  Am J Pathol       Date:  2021-01-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.